- Product Pipeline Review - H2 2011” provides a detailed overview on the Pluristem Therapeutics Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Pluristem Therapeutics Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Pluristem Therapeutics Inc. and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- Pluristem Therapeutics Inc. - Brief Pluristem Therapeutics Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pluristem Therapeutics Inc. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pluristem Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pluristem Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Pluristem Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pluristem Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pluristem Therapeutics Inc.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pluristem Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pluristem Therapeutics Inc. and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Pluristem Therapeutics Inc. Snapshot 7
Pluristem Therapeutics Inc. Overview 7
Key Information 7
Key Facts 7
Pluristem Therapeutics Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Pluristem Therapeutics Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pluristem Therapeutics Inc. - Pipeline Products Glance 12
Pluristem Therapeutics Inc. Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Pluristem Therapeutics Inc. - Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Pluristem Therapeutics Inc. - Drug Profiles 15
PLX For Muscle Trauma 15
PLX For Neuropathic Pain 16
PLX-ARS 17
PLX-DFU 19
PLX-MS 20
PLX-PAD 21
PLX-IBD 23
PLX-STROKE 24
Pluristem Therapeutics Inc. - Pipeline Analysis 25
Pluristem Therapeutics Inc. - Pipeline Products by Therapeutic Class 25
Pluristem Therapeutics Inc. - Pipeline Products by Route of Administration 27
Pluristem Therapeutics Inc. - Pipeline Products by Molecule Type 28
Pluristem Therapeutics Inc. - Recent Pipeline Updates 29
Pluristem Therapeutics Inc. - Dormant Projects 31
Pluristem Therapeutics Inc. - Locations And Subsidiaries 32
Head Office 32
Company's Recent Developments 33
Pluristem Therapeutics Inc., Recent Developments 33
August 25, 2011: Pluristem's PLX Cells Receives Orphan Drug Status For Treatment Of Buerger's Disease 33
January 18, 2011: Pluristem To Proceed To Phase II/III Clinical Trial In Critical Limb Ischemia Under Joint FDA-EMA Protocol, And Phase II Clinical Trial In Intermittent Claudication 34
March 15, 2011: Pluristem Therapeutics And NYU Medical Center Partner To Study Use Of PLX Cells In Treatment Of Diabetic Foot Ulcers 35
April 13, 2011: Pluristem Announces Encouraging Six-Month Follow-up Results Of Phase I Critical Limb Ischemia Clinical Trials 37
September 07, 2011: Pluristem’s PLX Cells Found To Have Potential To Treat Acute Radiation Syndrome 40
November 03, 2011: Pluristem Announces Positive 12-Month Data From Use Of PLX-PAD For Treatment Of Critical Limb Ischemia 41
January 03, 2011: Positive Pre-Clinical Data from Muscle Injury Study Moves Pluristem Toward Second Multi-Billion Dollar Clinical Indication 43
March 01, 2011: Pluristem Announces Positive Preclinical Data From Muscle Injury Study 44
Financial Deals Landscape 45
Pluristem Therapeutics Inc., Deals Summary 45
Pluristem Therapeutics Inc., Pharmaceuticals and Healthcare, Deal Details 47
Asset Transactions 47
Pluristem Takes Over Technology From Technion-Israel Institute of Technology And Weizmann Institute of Science 47
Private Equity 49
Pluristem Secures US$ 13.5 Mln In Private Equity Funding 49
Partnerships 51
Pluristem Therapeutics Enters Into Collaboration Agreement With Pharmicell 51
Pluristem Therapeutics Enters Into Research Agreement With Berlin-Brandenburg Center for Regenerative Therapies 52
Pluristem Therapeutics Enters Into Distribution Agreement With Biological Market 53
Licensing Agreements 54
Pluristem Therapeutics Enters Into Licensing Agreement With United Therapeutics 54
Pluristem Enters Into Licensing Agreement With Stem Cell Innovations For PLX I Technology 56
Pluristem Enters Into Technology Licensing Agreement With Stem Cell Innovations 57
Equity Offering 58
Pluristem Therapeutics Files Registration Statement For Public Offering Of Securities For US$ 150 Mln 58
Pluristem Therapeutics Completes An Underwritten Public Offering Of Units For US$ 41 Mln 60
Pluristem Therapeutics Completes First Tranche Of Placement Of US$ 1.2 Mln 63
Debt Offering 93
Pluristem Therapeutics Completes Private Placement Of Convertible Debentures For US$ 3 Mln 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 96

List of Tables

Pluristem Therapeutics Inc., Facts and Figures 7
Pluristem Therapeutics Inc., Key Facts 7
Pluristem Therapeutics Inc. - Pipeline by Therapy Area and Indication, H2 2011 9
Pluristem Therapeutics Inc. - Pipeline by Stage of Development, H2 2011 10
Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, H2 2011 11
Pluristem Therapeutics Inc. - Phase I, H2 2011 12
Pluristem Therapeutics Inc. - Pre-Clinical, H2 2011 13
Pluristem Therapeutics Inc. - Discovery, H2 2011 14
Pluristem Therapeutics Inc. - Pipeline By Therapeutic Class, H2 2011 26
Pluristem Therapeutics Inc. - Pipeline By Route of Administration, H2 2011 27
Pluristem Therapeutics Inc. - Pipeline By Molecule Type, H2 2011 28
Pluristem Therapeutics Inc. - Recent Pipeline Updates, H2 2011 29
Pluristem Therapeutics Inc. - Dormant Developmental Projects, 2010 31
Pluristem Therapeutics Inc., Deals Summary 45
Pluristem Takes Over Technology From Technion-Israel Institute of Technology And Weizmann Institute of Science 47
Pluristem Secures US$ 13.5 Mln In Private Equity Funding 49
Pluristem Therapeutics Enters Into Collaboration Agreement With Pharmicell 51
Pluristem Therapeutics Enters Into Research Agreement With Berlin-Brandenburg Center for Regenerative Therapies 52
Pluristem Therapeutics Enters Into Distribution Agreement With Biological Market 53
Pluristem Therapeutics Enters Into Licensing Agreement With United Therapeutics 54
Pluristem Enters Into Licensing Agreement With Stem Cell Innovations For PLX I Technology 56
Pluristem Enters Into Technology Licensing Agreement With Stem Cell Innovations 57
Pluristem Therapeutics Files Registration Statement For Public Offering Of Securities For US$ 150 Mln 58
Pluristem Therapeutics Completes An Underwritten Public Offering Of Units For US$ 41 Mln 60
Pluristem Therapeutics Completes First Tranche Of Placement Of US$ 1.2 Mln 63
Pluristem Therapeutics Completes Private Placement Of US$ 2.7 Mln 65
Pluristem Therapeutics Completes Registered Direct Offering Of US$ 3 Mln 66
Pluristem Therapeutics Completes Private Placement Of US$ 1.3 Mln 68
Pluristem Therapeutics Completes Private Placement Of US$ 1.2 Mln 70
Pluristem Therapeutics Completes Private Placement Of US$ 0.75 Mln 72
Pluristem Therapeutics Completes Private Placement Of US$ 1.04 Mln 73
Pluristem Therapeutics Completes Private Placement Of US$ 1.6 Mln 75
Pluristem Life Systems Raises US$ 1.14 Mln Through Exercise Of Warrants 77
Pluristem Therapeutics Completes Private Placement Of US$ 0.02 Mln 79
Pluristem Therapeutics Completes Private Placement Of US$ 0.08 Mln 81
Pluristem Therapeutics Completes Private Placement Of US$ 1.2 Mln 83
Pluristem Therapeutics Completes Private Placement Of US$ 1.12 Mln 85
Pluristem Therapeutics Completes Private Placement Of US$ 0.33 Mln 87
Pluristem Therapeutics Completes Private Placement Of US$ 0.43 Mln 89
Pluristem Life Systems Completes Private Placement Of US$ 1.5 Mln 91
Pluristem Therapeutics Completes Private Placement Of Convertible Debentures For US$ 3 Mln 93

List of Figures

Pluristem Therapeutics Inc. - Pipeline by Therapy Area and Indication, H2 2011 9
Pluristem Therapeutics Inc. - Pipeline by Stage of Development, H2 2011 10
Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, H2 2011 11
Pluristem Therapeutics Inc. - Pipeline By Therapeutic Class, H2 2011 25
Pluristem Therapeutics Inc. - Pipeline By Route of Administration, H2 2011 27

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing ...

JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.